Learn more about a new study claiming that GLP-1s could be used to treat cognitive conditions like dementia, but may pose a ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduc ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinfo ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

A safety committee will review all evidence from trials and studies to shed more light on the potential risk of NAION.

Health-care companies rose after more promising data for the best-selling Glucagon-like Peptide inhibitor drugs. Shares of Novo Nordisk and Eli Lilly, the two leading producers of GLP-1 drugs, rallied ...

Glucagon-like peptide-1 receptor agonist use corresponded with risk reductions for dozens of diseases and adverse health ...

A new study has considered some of the potential benefits and risks of glucagon-like peptide 1 receptor agonists (GLP-1RAs), ...

Coya Therapeutics, Inc. (NASDAQ:COYA) announced the expansion of its investigational pipeline and advancement of COYA 303 for ...

Weight loss drugs like Ozempic and Wegovy have been tied in a large, national study to a drop in the risk of developing dozens of health conditions. But the semaglutide-like drugs also appear to ...

The study revealed that weight-loss drugs significantly benefit neurological and behavioral health, including decreased risks ...

This cohort study found that key sociodemographic, health care, and clinical factors are associated with receipt of semaglutide, a ...